Gw Pharmaceuticals Share Discussion Threads

[nodding] 18/7/2016 15:18

Personally I am going to forget about GWP42004 until, and unless, GW says something about it. In fact I think I will go back to sleep until Q4.

Etarip, do you perchance have a connection with Penzance?

[wengerb] 14/7/2016 11:52

The earliest that the FDA could appove Epidiolex will be late-2017.

Success in treating glioma might well give a big boost. Positive news on cancer treatment always causes a stir.

The results of GWP's p2 trial are due in Q4 2016.

[masingi] 14/7/2016 10:33

Thanks, Wenger.
I'm looking for likely dates for the next positive news flow. I guess an announcement that the FDA approve Epidiolex for use would be pretty positive. Do you know how long after the pre-NDA meeting the FDA would give their verdict?

[wengerb] 14/7/2016 09:37

masingi. The second Dravet p3 will not read out until next year. That's not a problem as it's assumed that GWP will make an NDA (new drug application) to the FDA on the basis of one Dravet trial and two on L-GS.

Any day now GWPH is meeting the FDA for a pre-NDA meeting on the Dravet data. Needless to say, the successful L-GS data will also get a mention. I believe that there's a hope that the meeting might provide GWP with a go ahead for a combined Dravet/L-GS NDA ahead of the assumed timing for the NDA which currently is H1 2017.

[masingi] 14/7/2016 06:37

When is the second Dravet trial supposed to report?

[sojourno] 13/7/2016 21:30

Boscombe has given sound warning that more funds will be needed, the market response is a-ok imo. Good to see GS notifiable; that's a major draw.
FWIW I'm on the sidelines ATM having called the last significant RNS disgracefully wrong because I didn't bother reading it properly!
LOL.

[123prezzie] 13/7/2016 15:36

nodding, thank you for your honourable mention in post 8686. I had been hoping that the fund raise would be nearer the 696p ie. the price at which Justin sold all those options a year ago.
I did the review of the 30/09/15 GWP accounts for the UK shareholders association ( hxxp://www.uksa.org.uk/AIM_100 ). This review was not meant to comment on the investment case but merely to look at the quality of the information/presentation and to point up unanswered questions. I remain unhappy with the remuneration/options showered on our directors and point out that the current cash raise will only last for a year (depending on other sources of income, if any). Despite reservations I remain fully invested here.

[randompoint] 13/7/2016 13:38

Sam - you're not feeling the Piper Jaffrey warmth of "negative clarity"?

[cfb2] 13/7/2016 13:07

I think there was the possibility of selling the IP of GWP42004. With that door closed the fund raising was a likely consequence. Diabetic drug for GW was a distraction.

CFB

[samurai48] 13/7/2016 11:20

Very disappointed with the results of Type 2 Diabetes trial.

S

[ih_406638] 13/7/2016 08:34

Wenger, thanks for your 8680 post

[wengerb] 13/7/2016 08:25

FF. Thanks.

Let's hope that Goldman's subsidiary, Scopia, thinks that GWPH smells like money?

[future financier] 13/7/2016 08:21

Wenger - If I might correct your post in 8679 Goldman is "a great vampire squid wrapped around the face of humanity, relentlessly jamming its blood funnel into anything that smells like money"!

[wengerb] 13/7/2016 08:08

Disappointing news buried in the prospectus:

"In March 2014, we commenced a larger placebo-controlled Phase 2 dose ranging trial of GWP42004. The primary objective of this trial is to compare the change in glycemic control in patients with type-2 diabetes when treated with one of three doses of GWP42004 or placebo as add-on therapy, to metformin with the primary endpoint being change from baseline to the end of treatment in mean glycosylated hemoglobin A1c (HbA1c) level. The safety and tolerability of GWP42004 compared with placebo will also be assessed.

This trial is now completed and a preliminary analysis of the topline data shows that this trial did not meet its primary endpoint. The drug was well tolerated with no serious adverse events. We are undertaking further evaluation of the data to determine whether to pursue further development of GWP42004 within the field of type-2 diabetes."

[wengerb] 13/7/2016 07:43

I'm glad to see Goldman Sachs involved, the company may well be "a vampire squid sucking on the face of humanity" but it's a company that mixes with winners and, through a subsidiary, Scopia Management, Goldmn has built a 5% stake in GWPH.

[ih_406638] 13/7/2016 07:43

Price is $90 per ADS

[etarip] 13/7/2016 07:22

NASDAQ in after announcement and after hours trading at 8.00PM NY time ended at $95.50.

[ih_406638] 13/7/2016 05:45

It’s not entirely unexpected. They may want the cash for the new Epidiolex trials, but there are also extant trials coming to resolution this year. See post 8548 and the prescient post 8551 (well done 123Prezzie)

[bobo18] 12/7/2016 22:39

Wasn't expecting an offering of $150m of ADS....anyone any thoughts as to what they need the extra funds for?

[ih_406638] 12/7/2016 09:02

Well, he's been disappeared. It gives another meaning to post 8670

[neilrr] 11/7/2016 23:53

8669 was a C&P of an article about 10 biotech or 10 pharma stocks to watch, or something along those lines. It was posted by someone I don't recall posting here before, or at least not a regular.

[ih_406638] 11/7/2016 18:59

I can see post 8668, and post 8670, but not the one in between. Odd

[ih_406638] 11/7/2016 17:28

Lol. Or was it Leadsom holding us back?

[wengerb] 11/7/2016 15:39

Is this the "Theresa May effect" in action?